This page has only limited features, please log in for full access.

Unclaimed
Fabrizio Passamonti
Dipartimento di Medicina Veterinaria, Università degli Studi di Perugia, Via San Costanzo 4, 06126 Perugia, Italy

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Article
Published: 18 August 2021 in Journal of Clinical Microbiology
Reads 0
Downloads 0

Staphylococcus pseudintermedius is the primary cause of canine cutaneous infections and is sporadically isolated as a pathogen from humans. Rapidly emerging antibiotic-resistant strains are creating serious health concerns so that accurate and timely antimicrobial susceptibility testing (AST) is crucial for patient care.

ACS Style

Elisa Rampacci; Michele Trotta; Caterina Fani; Serenella Silvestri; Valentina Stefanetti; Chiara Brachelente; Antonella Mencacci; Fabrizio Passamonti. Comparative Performances of Vitek-2, Disk Diffusion, and Broth Microdilution for Antimicrobial Susceptibility Testing of Canine Staphylococcus pseudintermedius. Journal of Clinical Microbiology 2021, 59, 1 .

AMA Style

Elisa Rampacci, Michele Trotta, Caterina Fani, Serenella Silvestri, Valentina Stefanetti, Chiara Brachelente, Antonella Mencacci, Fabrizio Passamonti. Comparative Performances of Vitek-2, Disk Diffusion, and Broth Microdilution for Antimicrobial Susceptibility Testing of Canine Staphylococcus pseudintermedius. Journal of Clinical Microbiology. 2021; 59 (9):1.

Chicago/Turabian Style

Elisa Rampacci; Michele Trotta; Caterina Fani; Serenella Silvestri; Valentina Stefanetti; Chiara Brachelente; Antonella Mencacci; Fabrizio Passamonti. 2021. "Comparative Performances of Vitek-2, Disk Diffusion, and Broth Microdilution for Antimicrobial Susceptibility Testing of Canine Staphylococcus pseudintermedius." Journal of Clinical Microbiology 59, no. 9: 1.

Journal article
Published: 01 July 2021 in Viruses
Reads 0
Downloads 0

Maedi-visna virus (MVV) and caprine arthritis encephalitis virus (CAEV), referred to as small ruminant lentiviruses (SRLVs), belong to the genus Lentivirus of the Retroviridae family. SRLVs infect both sheep and goats, causing significant economic losses and animal welfare damage. Recent findings suggest an association between serological status and allelic variants of different genes such as TMEM154, TLR9, MYD88 and CCR5. The aim of this work was to investigate the role of specific polymorphisms of these genes in SRLVs infection in some sheep flocks in Italy. In addition to those already known, novel variants in the TMEM154 (P7H, I74V, I105V) gene were detected in this study. The risk of infection was determined finding an association between the serological status and polymorphisms P7H, E35K, N70I, I74V, I105V of TMEM154, R447Q, A462S and G520R in TLR9 gene, H176H* and K190K* in MYD88 genes, while no statistical association was observed for the 4-bp deletion of the CCR5 gene. Since no vaccines or treatments have been developed, a genetically based approach could be an innovative strategy to prevent and to control SRLVs infection. Our findings are an important starting point in order to define the genetic resistance profile towards SRLVs infection.

ACS Style

Chiara Arcangeli; Daniele Lucarelli; Martina Torricelli; Carla Sebastiani; Marcella Ciullo; Claudia Pellegrini; Andrea Felici; Silva Costarelli; Monica Giammarioli; Francesco Feliziani; Fabrizio Passamonti; Massimo Biagetti. First Survey of SNPs in TMEM154, TLR9, MYD88 and CCR5 Genes in Sheep Reared in Italy and Their Association with Resistance to SRLVs Infection. Viruses 2021, 13, 1290 .

AMA Style

Chiara Arcangeli, Daniele Lucarelli, Martina Torricelli, Carla Sebastiani, Marcella Ciullo, Claudia Pellegrini, Andrea Felici, Silva Costarelli, Monica Giammarioli, Francesco Feliziani, Fabrizio Passamonti, Massimo Biagetti. First Survey of SNPs in TMEM154, TLR9, MYD88 and CCR5 Genes in Sheep Reared in Italy and Their Association with Resistance to SRLVs Infection. Viruses. 2021; 13 (7):1290.

Chicago/Turabian Style

Chiara Arcangeli; Daniele Lucarelli; Martina Torricelli; Carla Sebastiani; Marcella Ciullo; Claudia Pellegrini; Andrea Felici; Silva Costarelli; Monica Giammarioli; Francesco Feliziani; Fabrizio Passamonti; Massimo Biagetti. 2021. "First Survey of SNPs in TMEM154, TLR9, MYD88 and CCR5 Genes in Sheep Reared in Italy and Their Association with Resistance to SRLVs Infection." Viruses 13, no. 7: 1290.

Journal article
Published: 20 May 2021 in Leukemia
Reads 0
Downloads 0

Anemia is a frequent manifestation of myelofibrosis (MF) and there is an unmet need for effective treatments in anemic MF patients. The REALISE phase 2 study (NCT02966353) evaluated the efficacy and safety of a novel ruxolitinib dosing strategy with a reduced starting dose with delayed up-titration in anemic MF patients. Fifty-one patients with primary MF (66.7%), post-essential thrombocythemia MF (21.6%), or post-polycythemia vera MF (11.8%) with palpable splenomegaly and hemoglobin <10 g/dl were included. Median age was 67 (45–88) years, 41.2% were female, and 18% were transfusion-dependent. Patients received 10 mg ruxolitinib b.i.d. for the first 12 weeks, then up-titrations of up to 25 mg b.i.d. were permitted, based on efficacy and platelet counts. Overall, 70% of patients achieved a ≥50% reduction in palpable spleen length at any time during the study. The most frequent adverse events leading to dose interruption/adjustment were thrombocytopenia (17.6%) and anemia (11.8%). Patients who had a dose increase had greater spleen size and higher white blood cell counts at baseline. Median hemoglobin levels remained stable and transfusion requirements did not increase compared with baseline. These results reinforce the notion that it is unnecessary to delay or withhold ruxolitinib because of co-existent or treatment-emergent anemia.

ACS Style

Francisco Cervantes; David M. Ross; Atanas Radinoff; Francesca Palandri; Alexandr Myasnikov; Alessandro M. Vannucchi; Pierre Zachee; Heinz Gisslinger; Norio Komatsu; Lynda Foltz; Francesco Mannelli; Francesco Passamonti; Geralyn Gilotti; Islam Sadek; Ranjan Tiwari; Evren Zor; Haifa Kathrin Al-Ali. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. Leukemia 2021, 1 -11.

AMA Style

Francisco Cervantes, David M. Ross, Atanas Radinoff, Francesca Palandri, Alexandr Myasnikov, Alessandro M. Vannucchi, Pierre Zachee, Heinz Gisslinger, Norio Komatsu, Lynda Foltz, Francesco Mannelli, Francesco Passamonti, Geralyn Gilotti, Islam Sadek, Ranjan Tiwari, Evren Zor, Haifa Kathrin Al-Ali. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. Leukemia. 2021; ():1-11.

Chicago/Turabian Style

Francisco Cervantes; David M. Ross; Atanas Radinoff; Francesca Palandri; Alexandr Myasnikov; Alessandro M. Vannucchi; Pierre Zachee; Heinz Gisslinger; Norio Komatsu; Lynda Foltz; Francesco Mannelli; Francesco Passamonti; Geralyn Gilotti; Islam Sadek; Ranjan Tiwari; Evren Zor; Haifa Kathrin Al-Ali. 2021. "Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study." Leukemia , no. : 1-11.

Original reports
Published: 10 April 2021 in Journal of Clinical Oncology
Reads 0
Downloads 0

PURPOSE Recurrently mutated genes and chromosomal abnormalities have been identified in myelodysplastic syndromes (MDS). We aim to integrate these genomic features into disease classification and prognostication. METHODS We retrospectively enrolled 2,043 patients. Using Bayesian networks and Dirichlet processes, we combined mutations in 47 genes with cytogenetic abnormalities to identify genetic associations and subgroups. Random-effects Cox proportional hazards multistate modeling was used for developing prognostic models. An independent validation on 318 cases was performed. RESULTS We identify eight MDS groups (clusters) according to specific genomic features. In five groups, dominant genomic features include splicing gene mutations ( SF3B1, SRSF2, and U2AF1) that occur early in disease history, determine specific phenotypes, and drive disease evolution. These groups display different prognosis (groups with SF3B1 mutations being associated with better survival). Specific co-mutation patterns account for clinical heterogeneity within SF3B1- and SRSF2-related MDS. MDS with complex karyotype and/or TP53 gene abnormalities and MDS with acute leukemia–like mutations show poorest prognosis. MDS with 5q deletion are clustered into two distinct groups according to the number of mutated genes and/or presence of TP53 mutations. By integrating 63 clinical and genomic variables, we define a novel prognostic model that generates personally tailored predictions of survival. The predicted and observed outcomes correlate well in internal cross-validation and in an independent external cohort. This model substantially improves predictive accuracy of currently available prognostic tools. We have created a Web portal that allows outcome predictions to be generated for user-defined constellations of genomic and clinical features. CONCLUSION Genomic landscape in MDS reveals distinct subgroups associated with specific clinical features and discrete patterns of evolution, providing a proof of concept for next-generation disease classification and prognosis.

ACS Style

Matteo Bersanelli; Erica Travaglino; Manja Meggendorfer; Tommaso Matteuzzi; Claudia Sala; Ettore Mosca; Chiara Chiereghin; Noemi Di Nanni; Matteo Gnocchi; Matteo Zampini; Marianna Rossi; Giulia Maggioni; Alberto Termanini; Emanuele Angelucci; Massimo Bernardi; Lorenza Borin; Benedetto Bruno; Francesca Bonifazi; Valeria Santini; Andrea Bacigalupo; Maria Teresa Voso; Esther Oliva; Marta Riva; Marta Ubezio; Lucio Morabito; Alessia Campagna; Claudia Saitta; Victor Savevski; Enrico Giampieri; Daniel Remondini; Francesco Passamonti; Fabio Ciceri; Niccolò Bolli; Alessandro Rambaldi; Wolfgang Kern; Shahram Kordasti; Francesc Sole; Laura Palomo; Guillermo Sanz; Armando Santoro; Uwe Platzbecker; Pierre Fenaux; Luciano Milanesi; Torsten Haferlach; Gastone Castellani; Matteo G. Della Porta. Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. Journal of Clinical Oncology 2021, 39, 1223 -1233.

AMA Style

Matteo Bersanelli, Erica Travaglino, Manja Meggendorfer, Tommaso Matteuzzi, Claudia Sala, Ettore Mosca, Chiara Chiereghin, Noemi Di Nanni, Matteo Gnocchi, Matteo Zampini, Marianna Rossi, Giulia Maggioni, Alberto Termanini, Emanuele Angelucci, Massimo Bernardi, Lorenza Borin, Benedetto Bruno, Francesca Bonifazi, Valeria Santini, Andrea Bacigalupo, Maria Teresa Voso, Esther Oliva, Marta Riva, Marta Ubezio, Lucio Morabito, Alessia Campagna, Claudia Saitta, Victor Savevski, Enrico Giampieri, Daniel Remondini, Francesco Passamonti, Fabio Ciceri, Niccolò Bolli, Alessandro Rambaldi, Wolfgang Kern, Shahram Kordasti, Francesc Sole, Laura Palomo, Guillermo Sanz, Armando Santoro, Uwe Platzbecker, Pierre Fenaux, Luciano Milanesi, Torsten Haferlach, Gastone Castellani, Matteo G. Della Porta. Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. Journal of Clinical Oncology. 2021; 39 (11):1223-1233.

Chicago/Turabian Style

Matteo Bersanelli; Erica Travaglino; Manja Meggendorfer; Tommaso Matteuzzi; Claudia Sala; Ettore Mosca; Chiara Chiereghin; Noemi Di Nanni; Matteo Gnocchi; Matteo Zampini; Marianna Rossi; Giulia Maggioni; Alberto Termanini; Emanuele Angelucci; Massimo Bernardi; Lorenza Borin; Benedetto Bruno; Francesca Bonifazi; Valeria Santini; Andrea Bacigalupo; Maria Teresa Voso; Esther Oliva; Marta Riva; Marta Ubezio; Lucio Morabito; Alessia Campagna; Claudia Saitta; Victor Savevski; Enrico Giampieri; Daniel Remondini; Francesco Passamonti; Fabio Ciceri; Niccolò Bolli; Alessandro Rambaldi; Wolfgang Kern; Shahram Kordasti; Francesc Sole; Laura Palomo; Guillermo Sanz; Armando Santoro; Uwe Platzbecker; Pierre Fenaux; Luciano Milanesi; Torsten Haferlach; Gastone Castellani; Matteo G. Della Porta. 2021. "Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes." Journal of Clinical Oncology 39, no. 11: 1223-1233.

Letter to the editor
Published: 05 November 2020 in Hematological Oncology
Reads 0
Downloads 0

Chronic Hepatitis C virus (HCV) infection has been associated with a variety of B‐cell non‐Hodgkin lymphomas (NHL), including indolent subtypes (mainly marginal‐zone lymphomas, MZL) and diffuse large B‐cell lymphoma (DLBCL). 1.This article is protected by copyright. All rights reserved.

ACS Style

Michele Merli; Dario Marino; Emanuele Cencini; Sara Rattotti; Costanza Fraenza; Paolo Grossi; Benedetta Bianchi; Barbara Mora; Roberta Sciarra; Silvia Finotto; Bianca Mecacci; Francesco Passamonti; Carlo Visco; Luca Arcaini. Direct‐acting antivirals in hepatitis C virus‐positive mantle cell lymphomas. Hematological Oncology 2020, 39, 263 -266.

AMA Style

Michele Merli, Dario Marino, Emanuele Cencini, Sara Rattotti, Costanza Fraenza, Paolo Grossi, Benedetta Bianchi, Barbara Mora, Roberta Sciarra, Silvia Finotto, Bianca Mecacci, Francesco Passamonti, Carlo Visco, Luca Arcaini. Direct‐acting antivirals in hepatitis C virus‐positive mantle cell lymphomas. Hematological Oncology. 2020; 39 (2):263-266.

Chicago/Turabian Style

Michele Merli; Dario Marino; Emanuele Cencini; Sara Rattotti; Costanza Fraenza; Paolo Grossi; Benedetta Bianchi; Barbara Mora; Roberta Sciarra; Silvia Finotto; Bianca Mecacci; Francesco Passamonti; Carlo Visco; Luca Arcaini. 2020. "Direct‐acting antivirals in hepatitis C virus‐positive mantle cell lymphomas." Hematological Oncology 39, no. 2: 263-266.

Journal article
Published: 10 August 2020 in Blood Advances
Reads 0
Downloads 0

Myeloproliferative neoplasms (MPNs) are the most frequent underlying causes of splanchnic vein thromboses (SVTs). MPN patients with SVTs (MPN-SVT) often have a unique presentation including younger age, female predominance, and low Janus kinase 2 (JAK2) mutation allele burden. This study aimed at identifying risk factors for adverse hematologic outcomes in MPN-SVT patients. We performed a retrospective study of a fully characterized cohort of MPN-SVT patients. The primary outcome was the incidence of evolution to myelofibrosis, acute leukemia, or death. Eighty patients were included in the testing cohort. Median follow-up was 11 years. Most of the patients were women with a mean age of 42 years and a diagnosis of polycythemia vera. The primary outcome was met in 13% of the patients and was associated with a JAK2V617F allele burden ≥50% (odds ratio [OR], 14.7) and presence of additional mutations in genes affecting chromatin/spliceosome (OR, 9). We identified high-risk patients (29% of the cohort) as those harboring at least 1 molecular risk factor: JAK2-mutant allele burden ≥50%, presence of chromatin/spliceosome/TP53 mutation. High-risk patients had worse event-free survival (81% vs 100%; P = .001) and overall survival at 10 years (89% vs 100%; P = .01) than low-risk patients. These results were confirmed in an independent validation cohort of 30 MPN-SVT patients. In conclusion, molecular profiling identified MPN-SVT patients with dismal outcome. In this high-risk population, a disease-modifying therapy should be taken into consideration to minimize the probability of transformation.

ACS Style

Pierre-Edouard Debureaux; Bruno Cassinat; Juliette Soret-Dulphy; Barbara Mora; Emmanuelle Verger; Nabih Maslah; Aurelie Plessier; Pierre-Emmanuel Rautou; Isabelle Ollivier-Hourman; Victor De Ledinghen; Odile Goria; Christophe Bureau; Claudia Siracusa; Dominique Valla; Stephane Giraudier; Francesco Passamonti; Jean-Jacques Kiladjian. Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. Blood Advances 2020, 4, 3708 -3715.

AMA Style

Pierre-Edouard Debureaux, Bruno Cassinat, Juliette Soret-Dulphy, Barbara Mora, Emmanuelle Verger, Nabih Maslah, Aurelie Plessier, Pierre-Emmanuel Rautou, Isabelle Ollivier-Hourman, Victor De Ledinghen, Odile Goria, Christophe Bureau, Claudia Siracusa, Dominique Valla, Stephane Giraudier, Francesco Passamonti, Jean-Jacques Kiladjian. Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. Blood Advances. 2020; 4 (15):3708-3715.

Chicago/Turabian Style

Pierre-Edouard Debureaux; Bruno Cassinat; Juliette Soret-Dulphy; Barbara Mora; Emmanuelle Verger; Nabih Maslah; Aurelie Plessier; Pierre-Emmanuel Rautou; Isabelle Ollivier-Hourman; Victor De Ledinghen; Odile Goria; Christophe Bureau; Claudia Siracusa; Dominique Valla; Stephane Giraudier; Francesco Passamonti; Jean-Jacques Kiladjian. 2020. "Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses." Blood Advances 4, no. 15: 3708-3715.

Review
Published: 06 August 2020 in Pathogens
Reads 0
Downloads 0

Nontuberculous mycobacteria (NTM) represent an increasingly prevalent etiology of soft tissue infections in animals and humans. NTM are widely distributed in the environment and while, for the most part, they behave as saprophytic organisms, in certain situations, they can be pathogenic, so much so that the incidence of NTM infections has surpassed that of Mycobacterium tuberculosis in developed countries. As a result, a growing body of the literature has focused attention on the critical role that drug susceptibility tests and infection models play in the design of appropriate therapeutic strategies against NTM diseases. This paper is an overview of the in vitro and in vivo models of NTM infection employed in the preclinical phase for early drug discovery and vaccine development. It summarizes alternative methods, not fully explored, for the characterization of anti-mycobacterial compounds.

ACS Style

Elisa Rampacci; Valentina Stefanetti; Fabrizio Passamonti; Marcela Henao-Tamayo. Preclinical Models of Nontuberculous Mycobacteria Infection for Early Drug Discovery and Vaccine Research. Pathogens 2020, 9, 641 .

AMA Style

Elisa Rampacci, Valentina Stefanetti, Fabrizio Passamonti, Marcela Henao-Tamayo. Preclinical Models of Nontuberculous Mycobacteria Infection for Early Drug Discovery and Vaccine Research. Pathogens. 2020; 9 (8):641.

Chicago/Turabian Style

Elisa Rampacci; Valentina Stefanetti; Fabrizio Passamonti; Marcela Henao-Tamayo. 2020. "Preclinical Models of Nontuberculous Mycobacteria Infection for Early Drug Discovery and Vaccine Research." Pathogens 9, no. 8: 641.

Journal article
Published: 24 July 2020 in European Journal of Public Health
Reads 0
Downloads 0

Background Pigs are considered the main reservoir of genotypes 3 and 4 of hepatitis E virus (HEV), which is the major cause of acute hepatitis of viral origin in humans worldwide. An increasing number of autochthonous HEV infections have been observed in recent years in industrialized countries, most likely as a result of zoonotic transmission through the consumption of raw or undercooked meat products. Methods Two hundred and thirty-three blood and liver samples were collected at four different local slaughterhouses from domestic pigs bred in Abruzzo, a region of south-central Italy, where there is the highest human seroprevalence to HEV compared with the rest of Italy. An indirect enzyme-linked immunosorbent assay kit was used for detecting anti-HEV IgG in the sera, while the presence of HEV RNA was investigated by performing a real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Results Between 87.3% and 100% of swine serum samples collected in different slaughterhouses of Abruzzo were positive for anti-HEV antibodies. Conversely, none of the liver samples collected from the same animals were positive for HEV by real-time RT-PCR. Conclusions The hypothesis of foodborne zoonotic transmission from local pigs as responsible for the hyperendemic status of Abruzzo cannot be corroborated. However, the high seroprevalence observed in pigs indicates that HEV is highly circulating in these territories. We propose to further investigate the role of wild fauna and trade in carrier pigs, and the maintenance of HEV virulence in the environment and meat supply chain to shed light on the possible sources of human infection and the degree of occupational risk.

ACS Style

Camillo Martino; Elisa Rampacci; Ilaria Pierini; Monica Giammarioli; Valentina Stefanetti; Doreene R Hyatt; Andrea Ianni; Giovanni Di Paolo; Mauro Coletti; Fabrizio Passamonti. Detection of anti-HEV antibodies and RNA of HEV in pigs from a hyperendemic Italian region with high human seroprevalence. European Journal of Public Health 2020, 31, 68 -72.

AMA Style

Camillo Martino, Elisa Rampacci, Ilaria Pierini, Monica Giammarioli, Valentina Stefanetti, Doreene R Hyatt, Andrea Ianni, Giovanni Di Paolo, Mauro Coletti, Fabrizio Passamonti. Detection of anti-HEV antibodies and RNA of HEV in pigs from a hyperendemic Italian region with high human seroprevalence. European Journal of Public Health. 2020; 31 (1):68-72.

Chicago/Turabian Style

Camillo Martino; Elisa Rampacci; Ilaria Pierini; Monica Giammarioli; Valentina Stefanetti; Doreene R Hyatt; Andrea Ianni; Giovanni Di Paolo; Mauro Coletti; Fabrizio Passamonti. 2020. "Detection of anti-HEV antibodies and RNA of HEV in pigs from a hyperendemic Italian region with high human seroprevalence." European Journal of Public Health 31, no. 1: 68-72.

Correspondence
Published: 03 July 2020 in Leukemia
Reads 0
Downloads 0

We read with interest the perspective by von Lilinfeld-Toal et al. that provides recommendations for the management of cancer patients during the coronavirus disease 2019 (COVID-19) pandemic, caused by the spreading of the coronavirus SARS-CoV-2 [1]. In asymptomatic patients treated with tyrosine kinase inhibitors, the EHA Infectious Disease Scientific Working Group recommended continuing the therapy unmodified. In case of severe COVID-19, the Authors would consider the JAK1/2 inhibitor (JAKi) ruxolitinib as therapy for hyperinflammation. By JAK1 inhibition, ruxolitinib had demonstrated to exert a broad anti-inflammatory activity against the myeloproliferative neoplasms (MPNs) cytokine storm and has been used in the setting of COVID-19 infection with positive results [2]. Conversely, ruxolitinib may affect the immune response by different effects on immune cells, including inhibition of differentiation, function, and migration of dendritic cells, reduced in vivo T-cell (regulatory, Th1 and Th17) frequency and cytokine production, inhibition of NK cells killing activity, proliferation, and cytokine production [3]. Philadelphia-negative MPNs include polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) [4] and are characterized by increased thrombotic risk, progressive splenomegaly/symptoms, and reduced survival [5]. In MF and PV, infections represent a frequent complication, due to disease-related factors and use of ruxolitinib [6]. To understand how the behavior of Italian hematologists towards MPN has changed during the COVID-19 pandemic, and how ruxolitinib was managed, the GIMEMA (Gruppo Italiano Malattie EMatologiche dell’Adulto) MPN Working Party e‐mailed to 239 hematologists, belonging to 102 Italian hematology institutions, an anonymous online questionnaire (Supplementary Table) of 28 multiple choice questions. The survey was completed by 92 (38.5%) hematologists from 63 different Centers. For MPN diagnosis, 93.5% of physicians continued to routinely assess JAK2, MPL, or CALR genotyping according to standard indications. During the pandemic, marrow biopsy was performed by 73.9% of respondents normally, by 10.9% only in the suspect of MF, and never by 14.1%. In PV patients, 65.2% of respondents prescribed phlebotomies with a hematocrit (HCT) target at ≤45%, while 32.6% accepted the target HCT to >48%, and 2.2% did not suggest phlebotomies at all during the pandemic. Hydroxyurea (HU) was started in all ET and PV patients at high thrombotic risk by 82.6% of hematologists; however, 13% started HU only if cardiovascular risk factors were concomitant to high-risk features. Conversely, >50% of the hematologists declared to postpone interferon (IFN) after the resolution of the pandemic (Fig. 1a). Instead, therapies already in place were not modified by the pandemic, with 93.5% and 88.8% of clinicians managing HU and IFN, respectively, according to routine practice. Only 2.2 and 5.6% of the hematologists suggested to discontinue HU or IFN, while 4.3 and 5.6% decreased their doses. Start of cytoreductive therapies in ET and PV patients (a) and start of ruxolitinib in MF and PV patients during the COVID-19 pandemic (b). HU hydroxyurea, IFN interferon, ET essential thrombocythemia, PV polycythemia vera, MF myelofibrosis. Survey data were collected and managed using the REDCap electronic data capture tools hosted at the GIMEMA Foundation. Most responders have >10 years of clinical experience on MPNs and >20 patients in annual follow-up for each disease. However, only 10.9% of the clinicians directly followed MPN patients affected by COVID-19. The start of ruxolitinib was postponed in 17.4% and 28.6% of MF and PV patients, respectively. (Fig. 1b). Before ruxolitinib start, 40.2% of the hematologists obtained a negative COVID-19 pharyngeal swab (Fig. 2a), while only 5.4% required a negative pharyngeal swab during ruxolitinib (Fig. 2b). For 79.8% of respondents, ruxolitinib has no negative effect on COVID-19 infection, for 10.1% a negative influence may be restricted to patients with MF and/or a great disease burden, while for 10.1% a negative effect may always be anticipated. In case of mild and moderate COVID-19 infection, 67% and 58.4% of respondents did not change therapy, respectively (Fig. 2c, d). Management of COVID-19 screening before (a) or during (b) ruxolitinib and management of ruxolitinib in case of mild (c) or moderate (d) COVID-19 infection. Mild infection: respiratory symptoms not requiring hospitalization. Moderate infection: hypoxia (SPO2 ≤94%) requiring ventilatory support but not mechanical ventilation. In MF patients with an allogeneic transplant already scheduled, only 8.8% of hematologists proceeded without delay, while 15.4% postponed the transplant to pandemic resolution. Regarding the use of phone contacts in place of in-person hematological visits, 12% of the hematologists believed that MF patients always require a full medical visit; this percentage decreases to 1.1% and to 0% when PV and ET were considered, respectively. Accordingly, 19.8%, 38%, and 50% of respondents converted >80% medical visits into phone follow-up in MF, PV, and ET patients, respectively. After the resolution of the pandemic, 67.3% of hematologists will implement the use of telemedicine (Supplementary Figure). Notably, we documented no substantial difference in practice in colleagues with more (>10) years of experience, or who followed COVID-19-positive patients, or who work in the northern Italian regions most affected by the pandemic. This remarkable uniformity is probably owed to homogeneous recommendations from the central government and from Italian Societies of Hematology and Transplantation. Diagnostic procedures remained consistent to standard criteria, with most patients receiving molecular and histology evaluations during the pandemic, as already described in Italy [4, 5, 7, 8]. The therapeutic approach was also adherent to international...

ACS Style

Francesca Palandri; Alfonso Piciocchi; Valerio De Stefano; Massimo Breccia; Guido Finazzi; Alessandra Iurlo; Paola Fazi; Stefano Soddu; Bruno Martino; Sergio Siragusa; Francesco Albano; Francesco Passamonti; Marco Vignetti; Alessandro M. Vannucchi. How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey. Leukemia 2020, 34, 2805 -2808.

AMA Style

Francesca Palandri, Alfonso Piciocchi, Valerio De Stefano, Massimo Breccia, Guido Finazzi, Alessandra Iurlo, Paola Fazi, Stefano Soddu, Bruno Martino, Sergio Siragusa, Francesco Albano, Francesco Passamonti, Marco Vignetti, Alessandro M. Vannucchi. How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey. Leukemia. 2020; 34 (10):2805-2808.

Chicago/Turabian Style

Francesca Palandri; Alfonso Piciocchi; Valerio De Stefano; Massimo Breccia; Guido Finazzi; Alessandra Iurlo; Paola Fazi; Stefano Soddu; Bruno Martino; Sergio Siragusa; Francesco Albano; Francesco Passamonti; Marco Vignetti; Alessandro M. Vannucchi. 2020. "How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey." Leukemia 34, no. 10: 2805-2808.

Original article
Published: 28 April 2020 in Leukemia & Lymphoma
Reads 0
Downloads 0

Recent studies have demonstrated feasibility and substantial benefit of direct-acting antivirals (DAAs) administration during or after first-line immune-chemotherapy (I-CT) in patients with hepatitis C virus (HCV)-positive diffuse large B-cell lymphomas (DLBCL). However, data on DAAs used during or after salvage treatments are still lacking. In this study we assessed clinical and virological outcome in 11 patients with relapsed (n = 7) or refractory (n = 4) HCV-positive DLBCL. DAAs were given either concurrently (n = 3) or subsequent (n = 8) to salvage I-CT. Most patients (10 of 11) received sofosbuvir-based regimens. All patients completed their planned courses of DAAs and achieved sustained virological response. DAAs were well tolerated, with no grade ≥2 adverse events. At a median follow-up of 3.6 years four patients died (4-year OS: 76%). In conclusion, we provide evidence that DAAs in HCV-positive relapsed/refractory DLBCL are extremely safe and effective, suggesting that they should be used if HCV eradication was not instituted before.

ACS Style

Michele Merli; Irene DeFrancesco; Carlo Visco; Caroline Besson; Alice Di Rocco; Annalisa Arcari; Antonello Sica; Emanuele Cencini; Maria Chiara Tisi; Marco Frigeni; Paolo Grossi; Benedetta Bianchi; Barbara Mora; Lorenza Bertù; Raffaele Bruno; Francesco Passamonti; Luca Arcaini. Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma. Leukemia & Lymphoma 2020, 61, 2122 -2128.

AMA Style

Michele Merli, Irene DeFrancesco, Carlo Visco, Caroline Besson, Alice Di Rocco, Annalisa Arcari, Antonello Sica, Emanuele Cencini, Maria Chiara Tisi, Marco Frigeni, Paolo Grossi, Benedetta Bianchi, Barbara Mora, Lorenza Bertù, Raffaele Bruno, Francesco Passamonti, Luca Arcaini. Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma. Leukemia & Lymphoma. 2020; 61 (9):2122-2128.

Chicago/Turabian Style

Michele Merli; Irene DeFrancesco; Carlo Visco; Caroline Besson; Alice Di Rocco; Annalisa Arcari; Antonello Sica; Emanuele Cencini; Maria Chiara Tisi; Marco Frigeni; Paolo Grossi; Benedetta Bianchi; Barbara Mora; Lorenza Bertù; Raffaele Bruno; Francesco Passamonti; Luca Arcaini. 2020. "Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma." Leukemia & Lymphoma 61, no. 9: 2122-2128.

Multicenter study
Published: 04 March 2020 in American Journal of Hematology
Reads 0
Downloads 0

Fedratinib is an oral, selective Janus kinase 2 (JAK2) inhibitor. The phase II JAKARTA2 study assessed fedratinib in patients with intermediate‐ or high‐risk myelofibrosis who were resistant or intolerant to prior ruxolitinib per investigator assessment. Patients received fedratinib 400 mg/day in 28‐day cycles. JAKARTA2 outcomes were initially reported using a last‐observation‐carried forward (LOCF) analysis in a “Per Protocol” population. This updated analysis of JAKARTA2 employs intention‐to‐treat analysis principles without LOCF for all treated patients (ITT Population; N=97) and for a patient subgroup who met more stringent definitions of prior ruxolitinib failure (Stringent Criteria Cohort; n=79). Median duration of prior ruxolitinib exposure was 10.7 months. The primary endpoint was spleen volume response rate (SVRR; ≥35% spleen volume decrease from baseline to end of cycle 6 [EOC6]). SVRR was 31% in the ITT Population and 30% in the Stringent Criteria Cohort. Median duration of spleen volume response was not reached. Symptom response rate (≥50% reduction from baseline to EOC6 in total symptom score on the modified Myelofibrosis Symptom Assessment Form) was 27%. Grade 3‐4 anemia and thrombocytopenia rates were 38% and 22%, respectively. Patients with advanced MF substantially pretreated with ruxolitinib attained robust spleen responses and reduced symptom burden with fedratinib. This article is protected by copyright. All rights reserved.

ACS Style

Claire N. Harrison; Nicolaas Schaap Md; Alessandro M. Vannucchi; Jean-Jacques Kiladjian; Eric Jourdan; Richard T. Silver; Harry C Schouten; Francesco Passamonti; Sonja Zweegman Md; Moshe Talpaz; Srdan Verstovsek Md; Shelonitda Rose; Juan Shen; Tymara Berry; Carrie Brownstein; Ruben A. Mesa; Jean‐Jacques Kiladjian Md; Harry C. Schouten Md. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. American Journal of Hematology 2020, 95, 594 -603.

AMA Style

Claire N. Harrison, Nicolaas Schaap Md, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Eric Jourdan, Richard T. Silver, Harry C Schouten, Francesco Passamonti, Sonja Zweegman Md, Moshe Talpaz, Srdan Verstovsek Md, Shelonitda Rose, Juan Shen, Tymara Berry, Carrie Brownstein, Ruben A. Mesa, Jean‐Jacques Kiladjian Md, Harry C. Schouten Md. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. American Journal of Hematology. 2020; 95 (6):594-603.

Chicago/Turabian Style

Claire N. Harrison; Nicolaas Schaap Md; Alessandro M. Vannucchi; Jean-Jacques Kiladjian; Eric Jourdan; Richard T. Silver; Harry C Schouten; Francesco Passamonti; Sonja Zweegman Md; Moshe Talpaz; Srdan Verstovsek Md; Shelonitda Rose; Juan Shen; Tymara Berry; Carrie Brownstein; Ruben A. Mesa; Jean‐Jacques Kiladjian Md; Harry C. Schouten Md. 2020. "Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure." American Journal of Hematology 95, no. 6: 594-603.

Journal article
Published: 04 December 2019 in Pathogens
Reads 0
Downloads 0

Microbial biofilm has been implicated in a wide range of chronic infections. In spite of the fact that Rhodococcus equi is a recognized cause of chronic disease in animals and humans, few studies have focused on the sessile phenotype of R. equi. The aim of this research was to phenotypically characterize the biofilm development of R. equi and its answerability for hypo-responsiveness to macrolides and rifampicin. Biofilm formation is initiated by bacterial adhesion to the surface. In this work, the ability of R. equi to adhere to the surface of human lung epithelial cells was detected by a fluorometric adhesion test performed on 40 clinical isolates. Subsequently, the capability of R. equi to produce biofilm was investigated by colorimetric, fluorescence and scanning electron microscopy analysis, revealing a general slow growth of rhodococcal biofilm and different sessile phenotypes among field isolates, some also including filamented bacteria. Azithromycin treatment produced a higher long-term inhibition and dissolution of R. equi biofilms than rifampicin, while the two antibiotics combined boosted the anti-biofilm effect in a statistically significant manner, although this was not equally effective for all R. equi isolates. Increasing the MIC concentrations of drugs tenfold alone and in combination did not completely eradicate pre-formed R. equi biofilms, while a rifampicin-resistant isolate produced an exceptionally abundant extracellular matrix. These results have strengthened the hypothesis that biofilm production may occur as an antibiotic tolerance system in R. equi, potentially determining persistence and, eventually, chronic infection.

ACS Style

Elisa Rampacci; Maria Luisa Marenzoni; Stefano Giovagnoli; Fabrizio Passamonti; Mauro Coletti; Donatella Pietrella. Phenotypic Characterization of Rhodococcus equi Biofilm Grown In Vitro and Inhibiting and Dissolving Activity of Azithromycin/Rifampicin Treatment. Pathogens 2019, 8, 284 .

AMA Style

Elisa Rampacci, Maria Luisa Marenzoni, Stefano Giovagnoli, Fabrizio Passamonti, Mauro Coletti, Donatella Pietrella. Phenotypic Characterization of Rhodococcus equi Biofilm Grown In Vitro and Inhibiting and Dissolving Activity of Azithromycin/Rifampicin Treatment. Pathogens. 2019; 8 (4):284.

Chicago/Turabian Style

Elisa Rampacci; Maria Luisa Marenzoni; Stefano Giovagnoli; Fabrizio Passamonti; Mauro Coletti; Donatella Pietrella. 2019. "Phenotypic Characterization of Rhodococcus equi Biofilm Grown In Vitro and Inhibiting and Dissolving Activity of Azithromycin/Rifampicin Treatment." Pathogens 8, no. 4: 284.

Journal article
Published: 16 November 2019 in Veterinary Record
Reads 0
Downloads 0

This study aimed to describe bacteria isolated from the reproductive tract of mares and to identify changes in antimicrobial susceptibility patterns to those antibiotics commonly used for the treatment of equine endometritis. A total of 4122 equine uterine swabs were collected from mares suffering from reproductive tract disorders in the period 2010–2017. Aerobic culture and antimicrobial susceptibility testing using agar disc diffusion were performed on each sample. Aerobic bacteria were isolated from 3171 of 4122 (76.9 per cent) samples. The most frequently isolated microorganisms were Escherichia coli (885/3171, 27.9 per cent) and Streptococcus equi subspecies zooepidemicus (791/3171, 24.9 per cent), confirming previous findings from the literature. Antimicrobial susceptibility patterns of E coli, S equi subspecies zooepidemicus and Klebsiella pneumoniae changed over time. A statistically significant decrease in antimicrobial efficacy of cefquinome against E coli was observed over the years, as well as of ampicillin, cefquinome and penicillin against S equi subspecies zooepidemicus. The high frequency of resistant bacteria isolated in the present work proceeds in the same way as indicated by surveillance data on the huge antibiotic use in Italy. As a result, testing and monitoring programmes of antimicrobial efficacy are crucial to consciously using antibiotics and preserving their effectiveness both for veterinary and human medicine.

ACS Style

Lorenzo Pisello; Elisa Rampacci; Valentina Stefanetti; Francesca Beccati; Doreene Rose Hyatt; Mauro Coletti; Fabrizio Passamonti. Temporal efficacy of antimicrobials against aerobic bacteria isolated from equine endometritis: an Italian retrospective analysis (2010-2017). Veterinary Record 2019, 185, 598 -598.

AMA Style

Lorenzo Pisello, Elisa Rampacci, Valentina Stefanetti, Francesca Beccati, Doreene Rose Hyatt, Mauro Coletti, Fabrizio Passamonti. Temporal efficacy of antimicrobials against aerobic bacteria isolated from equine endometritis: an Italian retrospective analysis (2010-2017). Veterinary Record. 2019; 185 (19):598-598.

Chicago/Turabian Style

Lorenzo Pisello; Elisa Rampacci; Valentina Stefanetti; Francesca Beccati; Doreene Rose Hyatt; Mauro Coletti; Fabrizio Passamonti. 2019. "Temporal efficacy of antimicrobials against aerobic bacteria isolated from equine endometritis: an Italian retrospective analysis (2010-2017)." Veterinary Record 185, no. 19: 598-598.

Editorial
Published: 17 October 2019 in American Journal of Hematology
Reads 0
Downloads 0
ACS Style

Michele Merli; Francesco Passamonti. A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good! American Journal of Hematology 2019, 94, 1303 -1305.

AMA Style

Michele Merli, Francesco Passamonti. A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good! American Journal of Hematology. 2019; 94 (12):1303-1305.

Chicago/Turabian Style

Michele Merli; Francesco Passamonti. 2019. "A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!" American Journal of Hematology 94, no. 12: 1303-1305.

Correspondence
Published: 02 October 2019 in American Journal of Hematology
Reads 0
Downloads 0
ACS Style

Barbara Mora; Paola Guglielmelli; Elisa Rumi; Margherita Maffioli; Daniela Barraco; Alessandro Rambaldi; Marianna Caramella; Rami S. Komrokji; Jean‐Jacques Kiladjian; Jason Gotlib; Alessandra Iurlo; Francisco Cervantes; Timothy Devos; Francesca Palandri; Valerio De Stefano; Marco Ruggeri; Richard T. Silver; Francesco Albano; Giulia Benevolo; Chiara Cavalloni; Silvia Uccella; Raffaella Accetta; Claudia Siracusa; Stefania Agnoli; Michele Merli; Tiziano Barbui; Lorenza Bertù; Mario Cazzola; Alessandro M. Vannucchi; Francesco Passamonti. Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group. American Journal of Hematology 2019, 95, 1 .

AMA Style

Barbara Mora, Paola Guglielmelli, Elisa Rumi, Margherita Maffioli, Daniela Barraco, Alessandro Rambaldi, Marianna Caramella, Rami S. Komrokji, Jean‐Jacques Kiladjian, Jason Gotlib, Alessandra Iurlo, Francisco Cervantes, Timothy Devos, Francesca Palandri, Valerio De Stefano, Marco Ruggeri, Richard T. Silver, Francesco Albano, Giulia Benevolo, Chiara Cavalloni, Silvia Uccella, Raffaella Accetta, Claudia Siracusa, Stefania Agnoli, Michele Merli, Tiziano Barbui, Lorenza Bertù, Mario Cazzola, Alessandro M. Vannucchi, Francesco Passamonti. Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group. American Journal of Hematology. 2019; 95 (1):1.

Chicago/Turabian Style

Barbara Mora; Paola Guglielmelli; Elisa Rumi; Margherita Maffioli; Daniela Barraco; Alessandro Rambaldi; Marianna Caramella; Rami S. Komrokji; Jean‐Jacques Kiladjian; Jason Gotlib; Alessandra Iurlo; Francisco Cervantes; Timothy Devos; Francesca Palandri; Valerio De Stefano; Marco Ruggeri; Richard T. Silver; Francesco Albano; Giulia Benevolo; Chiara Cavalloni; Silvia Uccella; Raffaella Accetta; Claudia Siracusa; Stefania Agnoli; Michele Merli; Tiziano Barbui; Lorenza Bertù; Mario Cazzola; Alessandro M. Vannucchi; Francesco Passamonti. 2019. "Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group." American Journal of Hematology 95, no. 1: 1.

Correspondence
Published: 09 June 2019 in American Journal of Hematology
Reads 0
Downloads 0
ACS Style

Giuseppe G. Loscocco; Francesco Mannelli; Paola Guglielmelli; Chiara Paoli; Ilaria Marone; Rosalba Cucci; Giacomo Coltro; Benedetta Sordi; Francesco Albano; Massimo Breccia; Valerio De Stefano; Guido Finazzi; Alessandra Iurlo; Bruno Martino; Francesca Palandri; Francesco Passamonti; Sergio Siragusa; Lara Mannelli; Duccio Fantoni; Paola Fazi; Sergio Amadori; Marco Vignetti; Tiziano Barbui; Alessandro M. Vannucchi. Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. American Journal of Hematology 2019, 94, E239 -E242.

AMA Style

Giuseppe G. Loscocco, Francesco Mannelli, Paola Guglielmelli, Chiara Paoli, Ilaria Marone, Rosalba Cucci, Giacomo Coltro, Benedetta Sordi, Francesco Albano, Massimo Breccia, Valerio De Stefano, Guido Finazzi, Alessandra Iurlo, Bruno Martino, Francesca Palandri, Francesco Passamonti, Sergio Siragusa, Lara Mannelli, Duccio Fantoni, Paola Fazi, Sergio Amadori, Marco Vignetti, Tiziano Barbui, Alessandro M. Vannucchi. Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. American Journal of Hematology. 2019; 94 (9):E239-E242.

Chicago/Turabian Style

Giuseppe G. Loscocco; Francesco Mannelli; Paola Guglielmelli; Chiara Paoli; Ilaria Marone; Rosalba Cucci; Giacomo Coltro; Benedetta Sordi; Francesco Albano; Massimo Breccia; Valerio De Stefano; Guido Finazzi; Alessandra Iurlo; Bruno Martino; Francesca Palandri; Francesco Passamonti; Sergio Siragusa; Lara Mannelli; Duccio Fantoni; Paola Fazi; Sergio Amadori; Marco Vignetti; Tiziano Barbui; Alessandro M. Vannucchi. 2019. "Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative." American Journal of Hematology 94, no. 9: E239-E242.

Original research
Published: 07 June 2019 in Cancer Medicine
Reads 0
Downloads 0

Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient‐years. When including non‐melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patient‐years. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM.

ACS Style

Barbara Mora; Elisa Rumi; Paola Guglielmelli; Daniela Barraco; Margherita Maffioli; Alessandro Rambaldi; Marianna Caramella; Rami Komrokji; Jason Gotlib; Jean Jacques Kiladjian; Francisco Cervantes; Timothy Devos; Francesca Palandri; Valerio De Stefano; Marco Ruggeri; Richard T. Silver; Giulia Benevolo; Francesco Albano; Chiara Cavalloni; Daniela Pietra; Tiziano Barbui; Giada Rotunno; Mario Cazzola; Alessandro Maria Vannucchi; Toni Giorgino; Francesco Passamonti. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Medicine 2019, 8, 4089 -4092.

AMA Style

Barbara Mora, Elisa Rumi, Paola Guglielmelli, Daniela Barraco, Margherita Maffioli, Alessandro Rambaldi, Marianna Caramella, Rami Komrokji, Jason Gotlib, Jean Jacques Kiladjian, Francisco Cervantes, Timothy Devos, Francesca Palandri, Valerio De Stefano, Marco Ruggeri, Richard T. Silver, Giulia Benevolo, Francesco Albano, Chiara Cavalloni, Daniela Pietra, Tiziano Barbui, Giada Rotunno, Mario Cazzola, Alessandro Maria Vannucchi, Toni Giorgino, Francesco Passamonti. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Medicine. 2019; 8 (9):4089-4092.

Chicago/Turabian Style

Barbara Mora; Elisa Rumi; Paola Guglielmelli; Daniela Barraco; Margherita Maffioli; Alessandro Rambaldi; Marianna Caramella; Rami Komrokji; Jason Gotlib; Jean Jacques Kiladjian; Francisco Cervantes; Timothy Devos; Francesca Palandri; Valerio De Stefano; Marco Ruggeri; Richard T. Silver; Giulia Benevolo; Francesco Albano; Chiara Cavalloni; Daniela Pietra; Tiziano Barbui; Giada Rotunno; Mario Cazzola; Alessandro Maria Vannucchi; Toni Giorgino; Francesco Passamonti. 2019. "Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients." Cancer Medicine 8, no. 9: 4089-4092.

Comment
Published: 16 May 2019 in Blood
Reads 0
Downloads 0

In this issue of Blood , [Gagelmann et al][1][1][2] describe an integrated clinical-molecular prognostic model (Myelofibrosis Transplant Scoring System [MTSS]) to predict outcome post stem cell transplant (SCT) in myelofibrosis (MF). MF is a clonal stem cell neoplasm with heterogeneous clinical

ACS Style

Francesco Passamonti. Stem cell transplant in MF: it’s time to personalize. Blood 2019, 133, 2118 -2120.

AMA Style

Francesco Passamonti. Stem cell transplant in MF: it’s time to personalize. Blood. 2019; 133 (20):2118-2120.

Chicago/Turabian Style

Francesco Passamonti. 2019. "Stem cell transplant in MF: it’s time to personalize." Blood 133, no. 20: 2118-2120.

Journal article
Published: 02 May 2019 in Parasites & Vectors
Reads 0
Downloads 0

The epidemiology of feline vector-borne pathogens (FeVBPs) has been less investigated in cats than in dogs. The present study assessed the prevalence of Rickettsia spp., Babesia spp., Cytauxzoon spp. and Leishmania infantum infections in cat populations living in central Italy, by molecular and serological tools. A total of 286 healthy cats were randomly selected from catteries and colonies in central Italy. Peripheral blood and conjunctival swab (CS) samples were collected during surgical procedures for regional neutering projects. Sera were analysed by IFAT to detect anti-Rickettsia felis, R. conorii, Babesia microti and Leishmania IgG antibodies using commercial and home-made antigens. DNA extracted from buffy coats (BCs) was tested for Rickettsia spp., and Piroplasmida species, including Cytauxzoon spp. and Babesia spp. by PCR. Buffy coats and CS samples were assayed by a nested (n)-PCR for Leishmania spp. Sixty-two cats (21.67%) were seropositive to at least one of the tested pathogens. The serological assay revealed 23 (8.04%) and 18 (6.29%) positive cats for R. felis and R. conorii, respectively, with low titers (1/64–1/128). No antibodies against B. microti were detected. Neither Rickettsia nor Piroplasmida DNA were amplified using the specific PCR assays. Thirty-one cats (10.83%) tested positive to anti-Leishmania IgG, with titers ranging from 1:40 to 1:160 and 45 animals (15.73%) tested positive to Leishmania CS n-PCR, whereas none of the animals tested positive to BC n-PCR. Considering the results obtained by IFAT and CS n-PCR, a moderate agreement between the two tests was detected (κ = 0.27). The results of the serological and molecular surveys showed a moderate exposure to Leishmania in the investigated cats and highlighted the limited molecular diagnostic value of BC versus CS samples for this pathogen. Conversely no evidence supported the circulation of Cytauxzoon spp. in domestic cats, in contrast with previous detections in European wild cats in the same areas monitored. The low positive titres for R. felis in association with no DNA BC amplification prevent speculation on the exposure of feline populations to this FeVBP due to the cross-reactivity existing within spotted fever group rickettsiosis (SFGR).

ACS Style

Giulia Morganti; Fabrizia Veronesi; Valentina Stefanetti; Trentina Di Muccio; Eleonora Fiorentino; Manuela Diaferia; Azzurra Santoro; Fabrizio Passamonti; Marina Gramiccia. Emerging feline vector-borne pathogens in Italy. Parasites & Vectors 2019, 12, 1 -9.

AMA Style

Giulia Morganti, Fabrizia Veronesi, Valentina Stefanetti, Trentina Di Muccio, Eleonora Fiorentino, Manuela Diaferia, Azzurra Santoro, Fabrizio Passamonti, Marina Gramiccia. Emerging feline vector-borne pathogens in Italy. Parasites & Vectors. 2019; 12 (1):1-9.

Chicago/Turabian Style

Giulia Morganti; Fabrizia Veronesi; Valentina Stefanetti; Trentina Di Muccio; Eleonora Fiorentino; Manuela Diaferia; Azzurra Santoro; Fabrizio Passamonti; Marina Gramiccia. 2019. "Emerging feline vector-borne pathogens in Italy." Parasites & Vectors 12, no. 1: 1-9.

Research article
Published: 18 March 2019 in Stem Cells International
Reads 0
Downloads 0

Background. Equine adipose-derived mesenchymal stromal cells (e-AdMSC) exhibit attractive proregenerative properties strongly related to the delivery of extracellular vesicles (EVs) that enclose different kinds of molecules including RNAs. In this study, we investigated small RNA content of EVs produced by e-AdMSC with the aim of speculating on their possible biological role. Methods. EVs were obtained by ultracentrifugation of the conditioned medium of e-AdMSC of 4 subjects. Transmission electron microscopy and scanning electron microscopy were performed to assess their size and nanostructure. RNA was isolated, enriched for small RNAs (Results. Electron microscopy showed the presence of vesicles ranging in size from 30 to 300 nm and expressing typical markers. RNA analysis revealed that ribosomal RNA was the most abundant fraction, followed by small nucleolar RNAs (snoRNAs, 13.67%). Miscellaneous RNA (misc_RNA) reached 4.57% of the total where Y RNA, RNaseP, and vault RNA represented the main categories. miRNAs were sequenced at a lower level (3.51%) as well as protein-coding genes (1.33%). Pathway analyses on the protein-coding fraction revealed a significant enrichment for the “ribosome” pathway followed by “oxidative phosphorylation.” Gene Ontology analysis showed enrichment for terms like “extracellular exosome,” “organelle envelope,” “RNA binding,” and “small molecule metabolic process.” The miRNA target pathway analysis revealed the presence of “signaling pathways regulating pluripotency of stem cells” coherent with the source of the samples. Conclusion. We herein demonstrated that e-AdMSC release EVs enclosing different subsets of small RNAs that potentially regulate a number of biological processes. These findings shed light on the role of EVs in the context of MSC biology.

ACS Style

Stefano Capomaccio; Katia Cappelli; Cinzia Bazzucchi; Mauro Coletti; Rodolfo Gialletti; Franco Moriconi; Fabrizio Passamonti; Marco Pepe; Stefano Petrini; Samanta Mecocci; Maurizio Silvestrelli; Luisa Pascucci. Equine Adipose-Derived Mesenchymal Stromal Cells Release Extracellular Vesicles Enclosing Different Subsets of Small RNAs. Stem Cells International 2019, 2019, 1 -12.

AMA Style

Stefano Capomaccio, Katia Cappelli, Cinzia Bazzucchi, Mauro Coletti, Rodolfo Gialletti, Franco Moriconi, Fabrizio Passamonti, Marco Pepe, Stefano Petrini, Samanta Mecocci, Maurizio Silvestrelli, Luisa Pascucci. Equine Adipose-Derived Mesenchymal Stromal Cells Release Extracellular Vesicles Enclosing Different Subsets of Small RNAs. Stem Cells International. 2019; 2019 ():1-12.

Chicago/Turabian Style

Stefano Capomaccio; Katia Cappelli; Cinzia Bazzucchi; Mauro Coletti; Rodolfo Gialletti; Franco Moriconi; Fabrizio Passamonti; Marco Pepe; Stefano Petrini; Samanta Mecocci; Maurizio Silvestrelli; Luisa Pascucci. 2019. "Equine Adipose-Derived Mesenchymal Stromal Cells Release Extracellular Vesicles Enclosing Different Subsets of Small RNAs." Stem Cells International 2019, no. : 1-12.